Drugs in Dev. Neurology
Phase I
Belgium 
Details : Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1 of CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) for the treatment of neuropathic pain.
Product Name : CFTX-1554
Product Type : Other Small Molecule
Upfront Cash : $40.0 million
February 03, 2023
Details : CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.
Product Name : CFTX-1554
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Details : CFTX-1554 is a novel inhibitor of AT2R, a clinically precedented target for the treatment of neuropathic pain. CFTX-1554 interacts more efficiently with the AT2R binding site, resulting in improved properties.
Product Name : CFTX-1554
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2022
Details : The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain p...
Product Name : CFTX-1554
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2022
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depres...
Product Name : SDI-118
Product Type : Other Small Molecule
Upfront Cash : $130.0 million
January 03, 2022
Details : RES19-T has shown to produce an acute response, restoring calcium homeostasis and synaptic plasticity, aim to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.
Product Name : RES19-T
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2021
Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion
Details : NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-ye...
Product Name : NVD-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 15, 2021
reMYND extends Series B funding to EUR 24 million
Details : Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.
Product Name : RES19-T
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 21, 2021
ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer’s Program
Details : RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.
Product Name : RES19-T
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2020
Reset All
